DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06301191

Unknown

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

The Effect of Semaglutide on Endothelial Function, Arterial Stiffness and Liver Indices in Patients Witn Type 2 Diabetes Mellitus and NAFLD

Lead sponsor

Attikon Hospital

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

50

estimated

Study population

MASH / NAFLD / liver fibrosis, Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•Comparison of arterial stiffness markers difference among treatment groups•Comparison of endothelial glycocalyx thickness difference among treatment groups•Liver stiffness (VCTE), change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06301191
Org study ID133/21-02-2022

Timeline

Milestones

Study start2022-03-01actual
Primary completion2023-03-01actual
Study first posted2024-03-08actual
Last update posted2024-03-08actual
Study completion2024-05-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

MASH / NAFLD / liver fibrosisType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted
Sampling methodProbability sample

Study population text

50 subjects with T2DM and NAFLD, who attended the Diabetes Outpatients Clinic were enrolled in the study. 25 patients will reciece semaglutide 1 mg (treatment group) and 25 patients will receive DPP-4 inhibitors (either linagliptin or alogliptin or vildagliptin or sitagliptin - control group). Exclusion criteria were malignancies, chronic inflammatory disease, chronic kidney disease (estimated glomerular filtration rate \<60 ml/min/m2 for a period of at least 90 days) peripheral vascular disease, retinopathy, and previous therapy with a Glucagon-like peptide-1 agonist. None of the female patients was on hormone replacement treatment.

Inclusion criteria

•Diabetes Mellitus type 2
•NAFLD

Exclusion criteria

•malignancies
•chronic inflammatory disease
•chronic kidney disease (estimated glomerular filtration rate <60 ml/min/m2 for a period of at least 90 days)
•peripheral vascular disease
•retinopathy
•previous therapy with a Glucagon-like peptide-1 agonist.
•None of the female patients was on hormone replacement treatment.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

MASH / liver
1
Cardiometabolic biomarkers
1
Other (unclassified)
1

MASH / liver

1 endpoint
Primary/protocol endpoint

Comparison of liver stiffness difference among treatment groups

Time frame:12 months

Liver stiffness (VCTE), change

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint

Comparison of arterial stiffness markers difference among treatment groups

Time frame:12 months

change from baseline, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Comparison of endothelial glycocalyx thickness difference among treatment groups

Time frame:12 months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.